Abstract
Background
The antiepileptic drug pregabalin is one of the best-selling pharmaceutical products worldwide. There are increasing concerns about its potential for misuse and dependence especially among patients with former or current substance use disorders (SUDs).
Objective
Our objective was to clarify the extent and pattern of pregabalin use as well as motives and predictors in this population.
Methods
We conducted a cross-sectional study with patients on a detoxification ward for illicit drugs at the Center for Psychiatry, Südwürttemberg, Ravensburg in southern Germany from August 2012 until July 2013. We used an extensive questionnaire, part of the Structured Clinical Interview for DSM-IV (Diagnostic and Statistical Manual of Mental Disorders, 4th edition) Axis I Disorders (SCID-I) and urine samples.
Results
Of the 253 participating patients, 56% had used pregabalin at least once. Of these, 92% had acquired it at least in part from illegal sources. The main motives for the use of pregabalin were the attenuation of opioid withdrawal symptoms, the augmentation of other psychotropic substances, and the psychotropic effects of pregabalin itself. Predictors for pregabalin use were opioid and sedative use as well as younger age. The criteria of dependency according to DSM-IV was met by 11% of pregabalin users and 13% of urine samples were positive for pregabalin.
Conclusions
Use of pregabalin is common among users of illicit drugs in large parts of southern Germany, with motives for use, acquisition, and mode of use suggesting misuse. The mode of use, especially intake of high doses and concomitant use of other drugs, poses a serious risk to this population, including the development of dependency.
Similar content being viewed by others
References
Fijalkowski L, Salat K, Podkowa A, Zareba P, Nowaczyk A. Potential role of selected antiepileptics used in neuropathic pain as human GABA transporter isoform 1 (GAT1) inhibitors-Molecular docking and pharmacodynamic studies. Eur J Pharm Sci. 2017;96:362–72. doi:10.1016/j.ejps.2016.10.004.
Gajraj NM. Pregabalin: its pharmacology and use in pain management. Anesth Analg. 2007;105:1805–15. doi:10.1213/01.ane.0000287643.13410.5e.
Freynhagen R, Backonja M, Schug S, Lyndon G, Parsons B, Watt S, et al. Pregabalin for the treatment of drug and alcohol withdrawal symptoms: a comprehensive review. CNS Drugs. 2016;30:1191–200. doi:10.1007/s40263-016-0390-z.
Evoy KE, Morrison MD, Saklad SR. Abuse and misuse of pregabalin and gabapentin. Drugs. 2017;77:403–26. doi:10.1007/s40265-017-0700-x.
Schjerning O, Rosenzweig M, Pottegard A, Damkier P, Nielsen J. Abuse potential of pregabalin: a systematic review. CNS Drugs. 2016;30:9–25. doi:10.1007/s40263-015-0303-6.
IMS Health HQ Limited. Top 20 global products 2015. 2015. https://www.imshealth.com/files/web/Corporate/News/Top-Line%20Market%20Data/Top_20_Global_Products_2015.pdf. Accessed 15 Sept 2017.
Wilens T, Zulauf C, Ryland D, Carrellas N, Catalina-Wellington I. Prescription medication misuse among opioid dependent patients seeking inpatient detoxification. Am J Addict. 2015;24:173–7. doi:10.1111/ajad.12159.
Baird CRW, Fox P, Colvin LA. Gabapentinoid abuse in order to potentiate the effect of methadone: a survey among substance misusers. Eur Addict Res. 2014;20:115–8. doi:10.1159/000355268.
Grosshans M, Lemenager T, Vollmert C, Kaemmerer N, Schreiner R, Mutschler J, et al. Pregabalin abuse among opiate addicted patients. Eur J Clin Pharmacol. 2013;69:2021–5. doi:10.1007/s00228-013-1578-5.
Abrahamsson T, Berge J, Ojehagen A, Hakansson A. Benzodiazepine, z-drug and pregabalin prescriptions and mortality among patients in opioid maintenance treatment-A nation-wide register-based open cohort study. Drug Alcohol Depend. 2017;174:58–64. doi:10.1016/j.drugalcdep.2017.01.013.
Hakkinen M, Vuori E, Kalso E, Gergov M, Ojanpera I. Profiles of pregabalin and gabapentin abuse by postmortem toxicology. Forensic Sci Int. 2014;241:1–6. doi:10.1016/j.forsciint.2014.04.028.
Barrett SP, Meisner JR, Stewart SH. What constitutes prescription drug misuse? Problems and pitfalls of current conceptualizations. Curr Drug Abuse Rev. 2008;1:255–62.
O’brien CP. Benzodiazepine use, abuse, and dependence. J Clin Psychiatry. 2005;66(Suppl 2):28–33.
Portenoy RK. Opioid therapy for chronic nonmalignant pain: a review of the critical issues. J Pain Symptom Manag. 1996;11:203–17.
Hoffmann F, Glaeske G. Benzodiazepine hypnotics, zolpidem and zopiclone on private prescriptions: use between 1993 and 2012. Nervenarzt. 2014;85:1402–9. doi:10.1007/s00115-014-4016-8.
Wittchen H-U, Wunderlich U, Gruschwitz S, Zaudig M. Strukturiertes Klinisches Interview für DSM-IV, Achse I: psychische Störungen, Interviewheft. Göttingen: Hogrefe; 1997.
Mutschler J, Gastberger S, Baumgartner MR, Grosshans M, Seifritz E, Quednow BB, Herdener M. Pregabalin use among opioid-addicted patients in Switzerland. J Clin Psychiatry. 2016;77:1202–3. doi:10.4088/JCP.15l10296.
Alblooshi H, Hulse GK, El Kashef A, Al Hashmi H, Shawky M, Al Ghaferi H, et al. The pattern of substance use disorder in the United Arab Emirates in 2015: results of a National Rehabilitation Centre cohort study. Subst Abuse Treat Prev Policy. 2016;11:19. doi:10.1186/s13011-016-0062-5.
Gahr M, Freudenmann RW, Hiemke C, Kolle MA, Schonfeldt-Lecuona C. Pregabalin abuse and dependence in Germany: results from a database query. Eur J Clin Pharmacol. 2013;69:1335–42. doi:10.1007/s00228-012-1464-6.
Wittchen H-U, Bühringer G, Rehm JT, Soyka M, Träder A, Trautmann S. The Social, clinical and treatment situation of opioid maintenance treatment in a prevalence sample of patients at baseline. Suchtmed. 2011;13:227–31.
Schifano F, D’Offizi S, Piccione M, Corazza O, Deluca P, Davey Z, et al. Is there a recreational misuse potential for pregabalin? Analysis of anecdotal online reports in comparison with related gabapentin and clonazepam data. Psychother Psychosom. 2011;80:118–22. doi:10.1159/000321079.
Hasanein P, Shakeri S. Pregabalin role in inhibition of morphine analgesic tolerance and physical dependency in rats. Eur J Pharmacol. 2014;742:113–7. doi:10.1016/j.ejphar.2014.08.030.
Vashchinkina E, Piippo O, Vekovischeva O, Krupitsky E, Ilyuk R, Neznanov N, et al. Addiction-related interactions of pregabalin with morphine in mice and humans: reinforcing and inhibiting effects. Addict Biol. 2017. doi:10.1111/adb.12538.
Kammerer N, Lemenager T, Grosshans M, Kiefer F, Hermann D. Pregabalin for the reduction of opiate withdrawal symptoms. Psychiatr Prax. 2012;39:351–2. doi:10.1055/s-0032-1305042.
Kapil V, Green JL, Le Lait M-C, Wood DM, Dargan PI. Misuse of the gamma-aminobutyric acid analogues baclofen, gabapentin and pregabalin in the UK. Br J Clin Pharmacol. 2014;78:190–1.
Schifano F. Misuse and abuse of pregabalin and gabapentin: cause for concern? CNS Drugs. 2014;28:491–6. doi:10.1007/s40263-014-0164-4.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Ethics approval
The study was approved by the appropriate research ethics committee of the University of Ulm (Application no. 184/12).
Informed consent
Written informed consent was obtained from all participants included in the study.
Conflict of interest
Brendan J. Snellgrove, Tilman Steinert, and Susanne Jaeger declare that there are no conflicts of interest.
Funding
No specific funding was received for this study.
Rights and permissions
About this article
Cite this article
Snellgrove, B.J., Steinert, T. & Jaeger, S. Pregabalin Use Among Users of Illicit Drugs: A Cross-Sectional Survey in Southern Germany. CNS Drugs 31, 891–898 (2017). https://doi.org/10.1007/s40263-017-0467-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40263-017-0467-3